Drug Profile
Research programme: central nervous system therapeutics - AbbVie/Rugen
Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Rugen Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autistic disorder; Obsessive-compulsive disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 28 Dec 2017 No recent reports of development identified for preclinical development in Autistic-disorder in China (PO)
- 28 Dec 2017 No recent reports of development identified for preclinical development in Obsessive-compulsive-disorders in China (PO)